Clinical Trial Search

Primary: Percentage of Participants in Whom we Could Quantify Hepatic Transport of 11C-CSar — 100; 100 percentage of participants

Primary: Number of Participants With Severe Adverse Events (AEs), Serious Adverse Events (SAEs), Drug-Related AEs, Deaths, Discontinuation of Study Drug Due to AE, Dose-Limiting…

Primary: Area Under Concentration-time Curve (AUC) of Interferon (IFN) Beta-1a From the Moment of Drug Administration Until 48 Hours and to Infinity(AUC(0-48) and AUC(0-∞)…

Primary: Safety and Tolerability — 21; 22 participants

Primary: OZ439 AUC0-∞ — 1230; 907; 398 ng*h/mL

Primary: Cmax — 34.96; 249.55 pg/mL

Primary: Number of Vaccinated Subjects Any Averse Events and by Location and Severity — 10; 10; 9; 0 participants

Primary: Area Under the Curve From Time 0 to the Last Quantifiable Sample, AUC(0-t) — 494.54; 528.43 nanogram (ng)*hour (hr)/milliliter (mL)

Primary: Percentage of Participants Who Experienced at Least 1 Treatment-Emergent Adverse Event — 0; 16.7; 0; 16.7 percentage of participants

Primary: Geometric Least Squares Mean Area Under the Plasma Drug Concentration-time Curve From Time Zero to Infinity (AUC0-∞) Following a Single IV Dose of Sugammadex — 339; 151…

Primary: Maximum Tolerated Dose (MTD) of Nintedanib and Afatinib Based on the Percentage of Participants Experienced Dose Limiting Toxicities — 0.0; 0.0; 0.0; 0.0 percentage of…

Primary: Distal Contractile Integral — 178.3; 272.3; 261.8 mmHg*s*cm

Primary: Cmax: Maximum Observed Plasma Concentration for Alogliptin — 57.82; 101.38; 44.24; 96.74 ng/mL

Primary: OZ439 Cmax — 1910; 827; 1930; 1440 ng/ml

Primary: Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs) — 2; 3; 1; 2 participants